Olfactive Biosolutions Hires COO; Enhances Senior Management Team

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, has hired David W. Allen, a long-time food industry executive, as its new Chief Operating Officer.

Mr. Allen joins Nils Lommerin, Olfactive’s President and CEO; along with Chris Hanson, Chief Technology Officer; Birgit Cameron, Chief Commercial Officer and John Mumaugh, Senior Vice President of Sales and Marketing on the company’s executive staff.

“We have built a world-class senior management team that is bringing our Pivit™ product to market early this year,” said Mr. Lommerin. “As we roll out our products for weight loss, lowering blood pressure and blood sugar, and alleviating other chronic conditions, Dave’s many years of experience in the food industry will be incredibly valuable to our young company as he synchronizes ingredient procurement, soft gel manufacturing, packaging and fulfilment partners to give our customers excellent service.”

Prior to joining Olfactive, Mr. Allen has overseen operations for a number of important companies, including Frito-Lay Corporation, Dell Computer and Del Monte Foods.

About Olfactive Biosolutions

Olfactive Biosolutions is the leader in harnessing food molecules to treat chronic diseases. It has developed world-leading receptor technology and expertise in both ectopic receptors in the gut, lungs, skin, heart, blood and elsewhere, and olfactory and taste receptors in the nose and tongue.

Its unique technology demonstrates how ectopic receptors often perform the same physiological tasks as active pharmaceutical ingredients or APIs, and what ligands activate or inhibit them.

To learn more, visit https://olfactive.bio or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250204346847/en/

Investor Contact:
Nils Lommerin
(949) 205-5776

Media Contact:
Deb Stapleton
(650) 815-1239
[email protected]

Source: Olfactive Biosolutions

You May Also Be Interested In

• Affinity Interactive Announces the Successful Transition of Primm Valley Casino Resorts’ Operations
• Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Provides New Details on FF’s Robotics Q3 Campaign, EAI Robotics Summer Camps and Insight Into FF’s Delivery, Service, an
• Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formu